INTRADAY TIPS FOR OCTOBER 29-10-2012 MONDAY

SCRIP

ACTION

TRIGGER

TARGET 1

TARGET 2

STOPLOS

ALLCARGO

BUY

131.50

133.25

136.00

130.00

IDFC

BUY

157.00

158.50

160.60

155.50

Monday, September 12, 2011

STOCKS IN NEWS FOR THIS WEEK

* The ONGC FPO issue is already attracting attention. The grey market premium on its proxy IPO application form of
Rs.2 lakh is commanding a premium of Rs.4600-4800 in Gujarat. This amounts to a 5% fixed return in only 20 days!

* Sarla Performance Fibres is expected to post an EPS of Rs.30 in FY12 on its small equity of Rs.7 crore. Its share cum 45%
dividend is an excellent buy and a strong bonus candidate too.

* IFB Ago shares are being cornered by the persons in the know. This spirit company is all set to post an EPS of Rs.35 in
the current fiscal and the share is poised to touch Rs.200 mark.

* One analyst strongly recommends the shares of Globus Spirits for the long-term. With an immediate target of Rs.160,
the share is likely to cross the Rs.200 mark in the medium-to-long-term.

* Repro India is expected to garner an EPS of Rs.35+ in FY12. The share is heading for a double century.

* Buy APM Industries and Ambika Cotton Mills as they are doing well in the current year and are likely to fetch a
decent gain of over 50% in the medium-term on their strong fundamentals.

* The shares of Ind-Swift Ltd are going cheap considering its expected sales of over Rs.1000 crore on its small equity of
Rs.8 crore. The share is available at a P/E multiple of just 2.5 on FY12 estimated EPS of Rs.12 on its Rs.2 paid-up share.

* Polyplex Corporation, which posted excellent results in Q1FY12, is all set to post consolidated EPS of Rs.90 in FY12.
Further expansion will push its EPS to Rs.110 in FY13. The share is worth adding to your portfolio.

* Ansal Housing is one share in the realty sector going dirt cheap. Based on the Q1FY12 results, the company is expected
to post consolidated EPS of over Rs.20 in FY12. The share is likely to appreciate by over 50%.

* Surya Pharma, whose plant is approved by the USFDA, is expected to notch an EPS of Rs.5.8 (FV Rs.1) in FY12. The
share is expected to double in the medium-to-long-term.

No comments:

Post a Comment